Evidence map›Paper›PMID 21459797›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011

Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification.

Na Yang, Shun Feng, Kerby Shedden, Xiaolei Xie, Yashu Liu, Charles J Rosser, David M Lubman, Steven Goodison

Open access · bronzeAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 149 citations in OpenAlex.

  1. Trial
  2. Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. The application of high-throughput proteomics in cytopathology.Journal of pathology and translational medicine · 2022
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Na YangDepartment of Surgery, University of Michigan Medical Center, University of Michigan, Ann Arbor, Michigan, USA.
Shun Feng
Kerby Shedden
Xiaolei Xie
Yashu Liu
Charles J Rosser
David M Lubman
Steven Goodison
University of Michigan–Ann Arbor · US

Funding

Towards a non-invasive molecular test for bladder cancerR01CA116161 · NCI · UNIVERSITY OF FLORIDA · PI GOODISON, STEVE · 2007 to 2019
$2.9M
Functional Analysis of metastasis-Associated ProteinsR01CA108597 · NCI · UNIVERSITY OF FLORIDA · PI GOODISON, STEVE · 2004 to 2008
$1.3M
NCI NIH HHS R01 CA108597NCI NIH HHS R01 CA116161
6 · The paper itself

Abstract

backgroundCancers of the urinary bladder are the fifth most commonly diagnosed malignancy in the United States. Early clinical diagnosis of bladder cancer remains a major challenge, and the development of noninvasive methods for detection and surveillance is desirable for both patients and health care providers. APPROACH: To identify urinary proteins with potential clinical utility, we enriched and profiled the glycoprotein component of urine samples by using a dual-lectin affinity chromatography and liquid chromatography/tandem mass spectrometry platform.

resultsFrom a primary sample set obtained from 54 cancer patients and 46 controls, a total of 265 distinct glycoproteins were identified with high confidence, and changes in glycoprotein abundance between groups were quantified by a label-free spectral counting method. Validation of candidate biomarker alpha-1-antitrypsin (A1AT) for disease association was done on an independent set of 70 samples (35 cancer cases) by using an ELISA. Increased levels of urinary A1AT glycoprotein were indicative of the presence of bladder cancer (P < 0.0001) and augmented voided urine cytology results. A1AT detection classified bladder cancer patients with a sensitivity of 74% and specificity of 80%. SUMMARY: The described strategy can enable higher resolution profiling of the proteome in biological fluids by reducing complexity. Application of glycoprotein enrichment provided novel candidates for further investigation as biomarkers for the noninvasive detection of bladder cancer.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinomaChromatography, LiquidFemaleGlycoproteinsHumansMaleMiddle AgedStaining and LabelingTandem Mass SpectrometryUrinalysisUrinary Bladder NeoplasmsYoung AdultBiomarkers, TumorGlycoproteins

Identifiers

PMID21459797
PMCPMC3096687
OpenAlexW2003103844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.